CIOREVIEW >> Pharma & life sciences >>

ValGenesis and Ambit-BST Collaborate to Address Paperless Life Science Needs

By CIOReview | Wednesday, July 15, 2020

The new strategic partnership of ValGenesis and Ambit-BST to innovate paperless momentum of the life science arena.

FREMONT, CA: One of the leading Enterprise Validation Lifecycle Management Solutions (VLMS) companies in the market, ValGenesis, Inc., collaborates with Ambit-BST, a digital technology specialist company that focuses on providing tailored information technology solutions and services to life science companies. This strategic partnership is expected to achieve the goal of 100% paperless validation for life science companies across Spain and Latin America.

The collaboration of ValGenesis and Ambit-BST fosters companies in the life science arena with the mastered and deep digital technology solutions featuring practical implementation skills and strategies that can help clients through successful business transformations.

Going paperless almost completely being the aim of the partnership, both the companies are committed to staying, in future, in tandem with the insights into developing new and favorable market situations. The partnership also provides comprehensive solutions to the pharma and life science sector.

The two partnered companies seem to be a fruitful combination of expertise and practical implementation, taking into consideration, robustness, reliability, innovation, comprehensibility, and digital validation. Together, ValGenesis and Ambit-BST march towards unleashing their complete potential and strengths pertaining to digital transformation to help their life science clients in Spain and Latin America.

The innovative software platform solution provider, ValGenesis, Inc., frames an expert foundation for monitoring all validation activities along with ensuring compliance in companies operating in the realm of life science. The company also holds the popularity of being the first enterprise application to manage and fulfill the process of corporate validation lifecycle. The new solution proves to be conforming with U.S. FDA 21 CFR Part 11 and Annex 11 requirements. Boasting to be the first entirely paperless solution in the midst of electronic management of validation execution and approval, the company and its collaboration is looked upon for mapping the imagination of innovation to the screens of reality.

See Also: Life Science Review